Related references
Note: Only part of the references are listed.Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer
Pradeep S. Tanwar et al.
CARCINOGENESIS (2014)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2014)
PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer-Results from NCIC CTG/AGITG CO.17
Christos S. Karapetis et al.
CLINICAL CANCER RESEARCH (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Hubing Shi et al.
CANCER DISCOVERY (2014)
PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia
Julie E. Chang et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
David Lebwohl et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012 (2013)
Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion
Yan Xie et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
Esther Castellano et al.
CANCER CELL (2013)
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
Filip Janku et al.
CANCER RESEARCH (2013)
RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
Ralph Fritsch et al.
CELL (2013)
Cell survival and metastasis regulation by Akt signaling in colorectal cancer
Ekta Agarwal et al.
CELLULAR SIGNALLING (2013)
PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis
Shuangjie Wu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Violeta Serra et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]midazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
Chudi O. Ndubaku et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial
Shuji Ogino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate
York Posor et al.
NATURE (2013)
Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase
Hashem A. Dbouk et al.
PLOS ONE (2013)
Genetic heterogeneity of diffuse large B-cell lymphoma
Jenny Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage
Ivan Angulo et al.
SCIENCE (2013)
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Vivian W. Y. Lui et al.
CANCER DISCOVERY (2013)
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
Clifford Hudis et al.
BREAST CANCER RESEARCH (2013)
LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer
Fanny Dupuy et al.
CANCER & METABOLISM (2013)
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
C. Mao et al.
ANNALS OF ONCOLOGY (2012)
Regulation and cellular functions of class II phosphoinositide 3-kinases
Marco Falasca et al.
BIOCHEMICAL JOURNAL (2012)
Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
Klaus P. Hoeflich et al.
CANCER RESEARCH (2012)
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Xiaoyun Liao et al.
CLINICAL CANCER RESEARCH (2012)
Second-line therapy for refractory renal-cell carcinoma
Fable Zustovich et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors
Dejan Juric et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
Filip Janku et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
Rodrigo Dienstmann et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
Saskia M. Brachmann et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function
Kazuaki Yoshioka et al.
NATURE MEDICINE (2012)
KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors
Ignacio Garrido-Laguna et al.
PLOS ONE (2012)
A New Dimension to Ras Function: A Novel Role for Nucleotide-Free Ras in Class II Phosphatidylinositol 3-Kinase Beta (PI3KC2β) Regulation
Katy A. Wong et al.
PLOS ONE (2012)
PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
Mary E. Urick et al.
CANCER RESEARCH (2011)
PTEN Level in Tumor Suppression: How Much Is Too Little?
Arkaitz Carracedo et al.
CANCER RESEARCH (2011)
A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies
John W. Moroney et al.
CLINICAL CANCER RESEARCH (2011)
Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
Phuong K. Morrow et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PI3Kinase signaling in glioblastoma
M. M. Lino et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
Jing Yuan et al.
MOLECULAR CANCER THERAPEUTICS (2011)
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2011)
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
B. Weigelt et al.
ONCOGENE (2011)
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
Lydia W. T. Cheung et al.
CANCER DISCOVERY (2011)
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
M. Christine Hollander et al.
NATURE REVIEWS CANCER (2011)
Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors
Julian Carretero et al.
CANCER CELL (2010)
MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC)
Ji-guang Zhang et al.
CLINICA CHIMICA ACTA (2010)
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
Carol O'Brien et al.
CLINICAL CANCER RESEARCH (2010)
Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer
Charlotte E. Edling et al.
CLINICAL CANCER RESEARCH (2010)
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type
Stefano Barbi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
IGF-1 Mediates PTEN Suppression and Enhances Cell Invasion and Proliferation via Activation of the IGF-1/PI3K/Akt Signaling Pathway in Pancreatic Cancer Cells
Jiachi Ma et al.
JOURNAL OF SURGICAL RESEARCH (2010)
Diverse somatic mutation patterns and pathway alterations in human cancers
Zhengyan Kan et al.
NATURE (2010)
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
Shivanni Kummar et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
The nuts and bolts of AGC protein kinases
Laura R. Pearce et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
The genetic basis of kidney cancer: a metabolic disease
W. Marston Linehan et al.
NATURE REVIEWS UROLOGY (2010)
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
Clare G. Fedele et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α
Minghao Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Phosphoinositide signalling in cancer: beyond PI3K and PTEN
Tom D. Bunney et al.
NATURE REVIEWS CANCER (2010)
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
Margaret A. Knowles et al.
CANCER AND METASTASIS REVIEWS (2009)
Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
Christina Gewinner et al.
CANCER CELL (2009)
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Bijay S. Jaiswal et al.
CANCER CELL (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
SHIP Regulates the Reciprocal Development of T Regulatory and Th17 Cells
Natasha R. Locke et al.
JOURNAL OF IMMUNOLOGY (2009)
Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110 alpha and are disrupted in oncogenic p85 mutants
Haiyan Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
Saskia M. Brachmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma
Gary R. Hudes et al.
SEMINARS IN ONCOLOGY (2009)
The regulation and function of Class III PI3Ks: novel roles for Vps34
Jonathan M. Backer
BIOCHEMICAL JOURNAL (2008)
PIK3CA cancer mutations display gender and tissue specificity patterns
Silvia Benvenuti et al.
HUMAN MUTATION (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
AKT1E17K in human solid tumours
F. E. Bleeker et al.
ONCOGENE (2008)
Class IPI3K in oncogenic cellular transformation
L. Zhao et al.
ONCOGENE (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
Li Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Phosphoinositide 3-Kinase p110β Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development
Elisa Ciraolo et al.
SCIENCE SIGNALING (2008)
The genomic landscapes of human breast and colorectal cancers
Laura D. Wood et al.
SCIENCE (2007)
Regulation of neuron survival through an intersectin-phosphoinositide 3'-kinase C2β-AKT pathway
Margaret Das et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
The role of phosphoinositide 3-kinase C2α in insulin signaling
Marco Falasca et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit
Nabil Miled et al.
SCIENCE (2007)
AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway
Ling-Zhi Liu et al.
CANCER RESEARCH (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers
Barbara Geering et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Biochemical characterization of the type I inositol polyphosphate 4-phosphatase C2 domain
Colin T. Shearn et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Signalling through class I PI3Ks in mammalian cells
P. T. Hawkins et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2006)
Phosphoinositides in cell regulation and membrane dynamics
Gilbert Di Paolo et al.
NATURE (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
BCR-ABL regulates phosphatidylinositol 3-kinase-p110γ transcription and activation and is required for proliferation and drug resistance
FB Hickey et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase
S Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
The class II phosphoinositide 3-kinase C2β is not essential for epidermal differentiation
K Harada et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 30H-kinase
T Nobukuni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase
MP Byfield et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
S Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia
P Sujobert et al.
BLOOD (2005)
Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit
SC Shekar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration
T Maffucci et al.
JOURNAL OF CELL BIOLOGY (2005)
Frequent mutation of the PIK3CA gene in ovarian and breast cancers
DA Levine et al.
CLINICAL CANCER RESEARCH (2005)
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
JW Lee et al.
ONCOGENE (2005)
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
SY Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
PTEN function: how normal cells control it and tumour cells lose it
NR Leslie et al.
BIOCHEMICAL JOURNAL (2004)
Deregulated Akt3 activity promotes development of malignant melanoma
JM Stahl et al.
CANCER RESEARCH (2004)
The activation of nuclear phosphoinositide 3-kinase C2β in all-trans-retinoic acid-differentiated HL-60 cells
D Visnjic et al.
FEBS LETTERS (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Interaction of Btk and Akt in B cell signaling
J Lindvall et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
P-Rex1, a PtdIns(3,4,5)P3- and Gβγ-regulated guanine-nucleotide exchange factor for Rac
HCE Welch et al.
CELL (2002)
Electrostatic control of the membrane targeting of C2 domains
D Murray et al.
MOLECULAR CELL (2002)
Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5′-phosphatase isoform that partners with the Grb2 adapter protein
Z Tu et al.
BLOOD (2001)
Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein kinase-1
MJ Wick et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ
ME Pacold et al.
CELL (2000)
A specific function for phosphatidylinositol 3-kinase α (p85α-p110α) in cell survival and for phosphatidylinositol 3-kinase β (p85α-p110β) in de novo DNA synthesis of human colon carcinoma cells
C Bénistant et al.
ONCOGENE (2000)
Share Paper
